Involvement of bradykinin and bradykinin B1 receptor in patients with endometriosis

xlomafota13 shared this article with you from Inoreader Involvement of bradykinin and bradykinin B1 receptor in patients with endometriosis Via Experimental and therapeutic medicine Exp Ther Med. 2021 Nov;22(5):1240. doi: 10.3892/etm.2021.10675. Epub 2021 Sep 1. ABSTRACT Endometriosis (EM), a benign aseptic inflammatory disease, is associated with the presence of endometrial foci. Pain, one of its typical symptoms, has been reported as a constant stressor, but the etiology and pathogenesis of EM-associated pain are unclear. In the present study, eutopic and ectopic endometrium samples from women with EM (n=50) and normal endometrium samples from control subjects (n=20) were collected. Serum levels of prostaglandin E2 (PGE2), prostaglandin F2α (PGF2α) and bradykinin (BK) were measured using commercial ELISA kits. The expression of the BKB1 receptor (BKB1R) protein was evaluated by immunohistochemical staining and western blot assay. The mRNA expression of BKB1R was measured by reverse transcription-quantitative PCR. The results revealed that there was a substantial increase in the protein an d mRNA expression of BKB1R, as well as the release of PGE2, PGF2α and BK in the blood, in the EM group compared with that in the control group. Moreover, PGE2, PGF2α and BK levels were significantly correlated with each other, as well as with the pain intensity of EM. The increased expression levels of BKB1R protein and mRNA were positively correlated with the pain degree of EM. Thus, these data indicated that BK and BKB1R were involved in the pathological onset of EM-associated pain and that they may play an important role in EM-related pain by inducing PGE2 and PGF2α. The data indicate a potential new therapeutic target for EM-related pain. PMID:34539836 | PMC:PMC8438668 | DOI:10.3892/etm.2021.10675 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.